Drug Trials in Frontotemporal Dementia: Can Industry, Academia, Families and Regulators Get on One Page?
In Washington, D.C., stakeholders in frontotemporal dementia came together to apply lessons learned from setbacks of Alzheimer’s drug development to the emerging field of therapy evaluation in FTD.
26-Apr-2016 1:05 PM EDT Add to Favorites
Last month, scientists gathered to powwow about where we are with FTD, DLB, and cerebrovascular disorders and how best to target research dollars to them. Researchers articulated funding priorities for each of these diseases, which will inform the...
21-Apr-2016 1:05 PM EDT Add to Favorites
A free, open online course on rare forms of dementia aims to spread knowledge while harnessing social learning.
18-Feb-2016 4:05 PM EST Add to Favorites
Studies report no reduction in the amyloid-β peptide or the plaques it forms. Hints of efficacy came from four people free of the ApoE4 risk gene for AD, and one patient who was on it for nearly two years. Meanwhile, scientists uncovered a new...
15-Feb-2016 11:05 AM EST Add to Favorites
Inhibiting the Rho kinases ROCK1 and ROCK2 with fasudil, a drug approved in China and Japan, stimulates tau autophagy in cell culture and flies.
9-Feb-2016 11:05 AM EST Add to Favorites
While regulators are trying to figure out what went wrong, independent chemists have dug into the mechanism of what may have been a "dirty" drug.
1-Feb-2016 10:05 AM EST Add to Favorites
The University of California San Diego’s incoming Alzheimer’s research czar talked with Alzforum about where he wants to take the embattled Alzheimer’s Disease Cooperative Study and neurodegeneration research in the region.
22-Jan-2016 11:05 AM EST Add to Favorites
While no cure is in sight, ALS experts see reason to feel hopeful about research progress and possible new treatments.
15-Jan-2016 4:05 PM EST Add to Favorites